Savara Inc (SVRA) Price

Merck Ramps Drug Pipeline Ahead of Patent Cliff

Merck is strategically expanding its drug pipeline to mitigate the anticipated revenue loss from its blockbuster drug Keytruda's 2028 patent expiration. The market is focused on the execution risk and the commercial success of new assets needed to replace the multi-billion dollar revenue stream.